20/20 HealthCare Partners
  • Home
  • What Differentiates 20/20 HCP
  • Team
  • Companies
    • Companies
    • Exits
  • News
  • Contact

20/20 HealthCare Partners

22 Apr2021

NYT: Meet Virtual Reality, Your New Physical Therapist

Written by 2020HCP.com. Posted in News

Meet Virtual Reality, Your New Physical Therapist

While use of the gaming technology for improving physical ailments is still in the early stages, it shows promise — and it’s fun.

By Alina Tugend

April 21, 2021

This article is part of our new series on the Future of Health Care, which examines changes in the medical field.

Four years ago, Michael Heinrich was riding his motorcycle on the University of Michigan campus when a rotted tree fell on him and snapped his neck, causing him to permanently lose use of the lower half of his body. He spent weeks in intensive care and then went to inpatient rehabilitation for more than two months,

About halfway through his rehab stint, his occupational therapist, Michael Blackstock, asked whether he was interested in trying virtual reality for his therapy. Mr. Heinrich, now 26 — who is returning for his master’s at the university — was game.

“What I really enjoyed was being an eagle trying to go through rings,” he said, describing a virtual reality experience. “From an emotional standpoint, coming off an injury where I lost the majority of the use of my body, V.R. pushed the boundaries of what I thought was possible.”

  • Continue Reading
19 Mar2021

SQZ Biotechnologies Reports 2020 Financial Results and Recent Advancements

Written by 2020HCP.com. Posted in News

WATERTOWN, Mass.–(BUSINESS WIRE)– SQZ Biotechnologies (NYSE: SQZ), a cell therapy company developing novel treatments for multiple therapeutic areas, today reported full year 2020 financial results and recent business highlights.

“In 2020, we experienced the most important moment in SQZ’s journey so far: dosing our first patient. This accomplishment was coupled with exciting progress across our pipeline and the transition to being a public company. Despite the many challenges of COVID-19, our team continued to maintain focus on our mission to create transformative cell therapies for patients, for which I am proud and thankful,” commented Armon Sharei, chief executive officer. “We have many exciting milestones ahead and are committed to delivering on SQZ’s potential for patients across diseases.”

  • Continue Reading
15 Mar2021

News: Variantyx Secures $20M in Funding for Whole Genome Sequencing Methodology, Advanced Testing Method that Diagnoses Genetic Disorders

Written by 2020HCP.com. Posted in News

Variantyx, a leader in high complexity hereditary disease testing, today announced that they secured $20M in funding for their Whole Genome Sequencing (WGS)-based testing methodology, an advanced genetic testing method currently used to diagnose rare inherited and neurological disorders. The series C funding round was led by GHS Fund (Quark Venture LP and GF Securities) and includes new investor, IBM Ventures and current investors, Pitango Venture Capital, New Era Capital Partners, 20/20 HealthCare Partners. Zafrira Avnur, PhD, Quark Venture Chief Scientific Officer & Partner, will join the Variantyx board of directors.

  • Continue Reading
11 Mar2021

SQZ Biotech to Present Preclinical Data on KRAS Tumor Targets and Next Generation SQZ eAPCs at the American Association for Cancer Research (AACR) 2021 Annual Meeting

Written by 2020HCP.com. Posted in News

WATERTOWN, Mass.–(BUSINESS WIRE)– SQZ Biotechnologies Company (NYSE: SQZ), a cell therapy company developing novel treatments for multiple therapeutic areas, today announced that its team will present data on the next generation SQZ™ APCs and the broader applicability of the APC platform at the American Association for Cancer Research (AACR) 2021 Annual Meeting being held virtually April 10-15, 2021. SQZ APC is a cell therapy platform that aims to induce powerful antigen specific CD8+ T cell responses. Two posters will highlight the additional functionality of enhanced APCs (eAPCs) and potential patient population expansion by leveraging multiple mRNA based cargos. A third poster describes SQZ APCs in development for additional tumor types targeting both G12D and G12V KRAS mutations.

  • Continue Reading
22 Dec2020

Variantyx Licenses IBM Technologies That Leverage AI for Somatic Analysis

Written by 2020HCP.com. Posted in News

Variantyx, the leader in high complexity hereditary disease testing, today announced that it has entered into a licensing agreement with IBM for technologies that leverage artificial intelligence for somatic analysis from which Variantyx intends to develop comprehensive tumor diagnostic solutions.

  • Continue Reading
  • 1
  • ...
  • 7
  • 8
  • 9
  • 10
  • ...
  • 13

Latest News

  • Variantyx Secures $20M Debt Financing to Support Precision Medicine in North America, Europe October 18, 2022
  • SQZ Biotechnologies Presents Celiac Disease Tolerizing Antigen Carrier Preclinical Data at 2022 Federation of Clinical Immunology Societies (FOCIS) Annual Meeting June 21, 2022
  • SQZ Biotechnologies Receives FDA Fast Track Designation for its Lead Cell Therapy Candidate for the Treatment of HPV16+ Tumors April 28, 2022
  • SQZ Biotechnologies Presents New eAPC Preclinical Data Demonstrating That Multiplexed mRNA Engineering of Immune Cells Increases Killer T Cell Activity In Vivo April 11, 2022
  • SQZ Biotechnologies Publishes Comprehensive Preclinical Research on SQZ® TAC Platform’s Ability to Induce Multiple Key Mechanisms of Antigen-Specific Tolerance and Protect Against Type 1 Diabetes April 5, 2022

20/20 HealthCare Partners | 2000 Commonwealth Ave, Suite 200, Auburndale, MA 02466 | Contact Us

Copyright © 2019
  • Home
  • What Differentiates 20/20 HCP
  • Team
  • Companies
    • Companies
    • Exits
  • News
  • Contact